Real Time PCR Detects Relapse of JAK2 V617F Myelofibrosis Earlier Than Pyrosequencing after Allogeneic Transplantation

Shah, Mithun Vinod; Patel, Keyur P.; Luthra, Raja; Shamanna, Rashmi Kanagal; Mehrotra, Meenakshi; Champlin, Richard E.; Verstovšek, Srđan; Popat, Uday

doi:10.1016/j.bbmt.2016.12.217

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, in a cohort of 30 MF allo-HCT patients, the detection of a JAK2 V617F allele burden >1% on day +28 was associated with a higher risk of relapse and worse overall outcomes (37). Shah et al suggested that detection of a JAK2 V617 allele burden of >0•05% by allele specific (AS) qPCR within the first 180 days post-transplant would be the optimal cut-off point to identify patients at risk of relapse (38). The largest study, reported from the Hamburg group, investigated the value of MRD analysis in 136 patients undergoing RIC allo-HCT.…”

Section: Mrd Monitoring In Mf Allo-hct-jak2/calr/mplmentioning

confidence: 99%

Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party

et al. 2021

View full text Add to dashboard Cite

Allogeneic Haematopoietic Cell Transplantation (allo-HCT) remains the only curative approach in Myelofibrosis (MF). Despite advances over recent decades, relapse and non-relapse mortality rates remain significant. Relapse rates vary between 15% and 25% across retrospective studies and management strategies vary widely, ranging from palliation to adoptive immunotherapy and, in some cases, a second allo-HCT. Moreover, in allo-HCT, there is a higher incidence of poor graft function and graft failure due to splenomegaly and a hostile 'pro-inflammatory' marrow niche. The Practice Harmonisation and Guidelines subcommittee of the Chronic Malignancies Working Party (CMWP) of EBMT convened an international panel consisting of transplant haematologists, histopathologists and molecular biologists to propose practical, clinically relevant definitions of graft failure, poor graft function and relapse as well as management strategies following allo-HCT. A systematic approach to molecular monitoring, histopathological assessment and chimerism testing is proposed. These proposed recommendations aim to increase the accuracy and uniformity of reporting and to thereby facilitate the development of more consistent approaches to these challenging issues. In addition, we propose management strategies for these complications.

show abstract

Section: Mrd Monitoring In Mf Allo-hct-jak2/calr/mplmentioning

confidence: 99%